RBC Capital analyst Alistair Campbell lowered the firm’s price target on Genmab to DKK 2,400 from DKK 2,500 and keeps a Sector Perform rating on the shares.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
See the top stocks recommended by analysts >>
Read More on GMAB:
